Chong Kun Dang Pharmaceutical Corp.
š°š·South Korea
- Country
- š°š·South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06695598
- Locations
- š°š·
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect of CKD-379
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT06652971
- Locations
- š°š·
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Phase 3
Not yet recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: sacubitril/valsatran(dose maintenance)Drug: sacubitril/valsartan(dose increasing)
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 324
- Registration Number
- NCT06643819
- Locations
- š°š·
Wonju Severance Christian Hospital, Wonju, Korea, Republic of
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: CKD-383(Fed)Drug: CKD-383(Fasted)
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06492655
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 45
- Registration Number
- NCT06483243
- Locations
- š°š·
Chung-Ang University Gwangmyeong Hospital, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of EsoDuoĀ®
Phase 4
Recruiting
- Conditions
- Gastro Esophageal Reflux
- Interventions
- Drug: EsoDuoĀ® Tablet
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 180
- Registration Number
- NCT06430047
- Locations
- š°š·
Asan Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Telmisartan Compared With Losartan
Phase 4
Recruiting
- Conditions
- Diabetic NephropathiesHypertension
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 98
- Registration Number
- NCT06431477
- Locations
- š°š·
Severance Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions
Phase 1
Completed
- Conditions
- Endocrine, Nutritional and Metabolic Diseases
- Interventions
- Drug: D484
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT06399068
- Locations
- š°š·
Bumin Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Endocrine, Nutritional and Metabolic Diseases
- Interventions
- Drug: D484
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 37
- Registration Number
- NCT06399055
- Locations
- š°š·
Bumin Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect of CKD-378
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-378, QD, PO
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT06386328
- Locations
- š°š·
Gimpo Woori hospital, Gimpo-si, Gyeonggi-do, Korea, Republic of
Ā© Copyright 2025. All Rights Reserved by MedPath